234 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
IONS Ionis Pharmaceuticals, Inc. $48.21 $6.62B N/A
Article Searches
Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings? http://www.zacks.com/stock/news/226771/celldex-cldx-whats-ahead-for-the-stock-in-q2-earnings?cid=CS-ZC-FT-226771 Aug 04, 2016 - With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
ION Geophysical's (IO) CEO Brian Hanson on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3996942-ion-geophysicals-io-ceo-brian-hanson-q2-2016-results-earnings-call-transcript?source=feed_all_articles Aug 07, 2016 - ION Geophysical Corporation (NYSE:IO) Q2 2016 Earnings Conference Call August 4, 2016 10:00 AM ET Executives Karen Abercrombie - Vice President-Communications Brian Hanson - President and Chief Execut
Ionis Pharma Lipid Disorder Candidate Positive in Phase III http://www.zacks.com/stock/news/252094/ionis-pharma-lipid-disorder-candidate-positive-in-phase-iii?cid=CS-ZC-FT-252094 Mar 08, 2017 - Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed http://www.zacks.com/stock/news/256797/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-on-oncomed?cid=CS-ZC-FT-256797 Apr 19, 2017 - Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.
Why Ionis (IONS) Might Surprise This Earnings Season http://www.zacks.com/stock/news/259669/why-ionis-ions-might-surprise-this-earnings-season?cid=CS-ZC-FT-259669 May 08, 2017 - Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings? http://www.zacks.com/stock/news/259787/whats-in-store-for-immune-design-imdz-stock-in-q1-earnings?cid=CS-ZC-FT-259787 May 08, 2017 - Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.
Qualcomm announces strategic investment in lithium-ion batteries https://seekingalpha.com/news/3274511-qualcomm-announces-strategic-investment-lithium-ion-batteries?source=feed_news_all Jun 20, 2017 - Qualcomm (NASDAQ:QCOM) announces an investment in lithium-ion battery company Amionx. Financial terms were not disclosed, but Qualcomm President Derek Aberle will join the Amionx board. Amionx create
How Biogen Inc. Makes Most of Its Money https://www.fool.com/investing/2017/07/13/how-biogen-inc-makes-most-of-its-money.aspx?source=iedfolrf0000001 Jul 13, 2017 - A concentrated revenue source puts the biotech in need of diversification.
4 Reasons the AveXis Inc. Rally Could Continue https://www.fool.com/investing/2017/07/01/4-reasons-the-avexis-inc-rally-could-continue.aspx?source=iedfolrf0000001 Jul 01, 2017 - AveXis Inc. stock has more than doubled over the past year. Here's why it could climb even further.

Pages: 12345678910...24

<<<Page 5>